undamentalytics Newsletter
Sign in

Neurocrine Biosciences Inc revenue

Neurocrine Biosciences Inc's revenue was $2.86bn in fiscal 2025, up 21.4% on the year before. Since fiscal 2009 ($3.0m) it has grown at a compound 53.7% a year. Over the last twelve months it was $3.70bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue33477533020151624517881,0461,1341,4891,8872,3552,8613,702
Growth on the year before—+>999%+131.1%−31.4%−94.5%−100.0%—−24.1%+977.5%+179.2%+74.7%+32.7%+8.4%+31.3%+26.8%+24.8%+21.4%—
Gross profit———————15160446—1,0361,1191,4661,8472,3212,808—
Gross margin———————100.0%99.2%98.9%—99.0%98.7%98.4%97.9%98.6%98.2%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $2.8B 99.1% ▲ 21.6%
Collaboration Revenue $26.6M 0.9% ▲ 7.7%

From Neurocrine Biosciences Inc's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Neurocrine Biosciences Inc $3.70bn 38.0% 27.5%
Biomarin Pharmaceutical Inc $3.41bn 11.2% 15.1%
Argenx SE $4.15bn 89.9% —
Biontech SE $3.24bn 9.0% —
United Therapeutics Corp $3.15bn 2.5% 14.3%
Natera, Inc. $2.71bn 37.8% 42.7%

Compare with peers

Head to head: BMRN vs NBIXARGX vs NBIXBNTX vs NBIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neurocrine Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neurocrine Biosciences Inc.